Thousands of patients to benefit from new daily pill for serious heart condition following co-ordinated MHRA and NICE decisions
RegulatoryapprovedAficamtenPositive
AI Analysis
Summary
Aficamten has been approved by the MHRA and recommended by NICE for the treatment of a serious heart condition, with coordinated decisions between the two UK regulatory organizations enabling simultaneous authorization of this daily oral medication.
Outcome Details
MHRA approval and NICE recommendation for Aficamten
Importance:8/10
Sentiment:
0.85
MHRA approvalNICE recommendationcardiovascularregulatory approval
Read the original article
Published by MHRA (UK) on July 30, 2026 9:42 AM